# A Clinical Study on the Efficacy and Safety of Fasudil Hydrochloride Combined With Immunotherapy in the Treatment of Metastatic Castration-resistant Prostate Cancer

> **NCT07250542** · PHASE2 · RECRUITING · sponsor: **baotai Liang** · enrollment: 30 (estimated)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Fasudil hydrochloride combined with immunotherapy

## Key facts

- **NCT ID:** NCT07250542
- **Lead sponsor:** baotai Liang
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-07-05
- **Primary completion:** 2025-12-30
- **Final completion:** 2026-12-30
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-11-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07250542

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07250542, "A Clinical Study on the Efficacy and Safety of Fasudil Hydrochloride Combined With Immunotherapy in the Treatment of Metastatic Castration-resistant Prostate Cancer". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT07250542. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*